Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CMP-CPS-001 in Healthy Volunteers and OTC Deficiency
NCT06247670Phase 1Active, not recruiting
- Sponsor
- CAMP4 Therapeutics
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CMP-CPS-001 in ornithine transcarbamylase deficiency (4 arms), sponsored by CAMP4 Therapeutics. Primary endpoint: Adverse Events at 112 days. Started Feb 2024; status: active, not recruiting.
02
Drugs
CMP-CPS-001
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on NCT06247670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247670.